A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Solid Tumors|Advanced Triple Negative Breast Cancer|Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer|Advanced Metastatic Castration-Resistant Prostate Cancer|Advanced Platinum-Resistant Ovarian Cancer
Interventions: DRUG: TRX518|DRUG: Cyclophosphamide|DRUG: Avelumab
Sponsor: Leap Therapeutics, Inc.
Collaborators: Pfizer|Merck KGaA, Darmstadt, Germany